Bicycle Therapeutics (BCYC)

• Market cap: $925M
• 1 day: 4.86%
• 5 days: 4.61%
• 1 month: -4.36%
• 3 months: -42.90%
• 6 months: -44.92%
• Year to date: -6.75%
• 1 year: -23.27%
• 5 years: 23.07%
• 10 years: 11.58%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Employees: 284

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

40% more call options, than puts

Call options by funds: $793K | Put options by funds: $567K

10% more capital invested

Capital invested by funds: $829M [Q2] → $915M (+$86.4M) [Q3]

3% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 33

0% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 18

1% less funds holding

Funds holding: 106 [Q2] → 105 (-1) [Q3]

5.87% less ownership

Funds ownership: 91.03% [Q2] → 85.16% (-5.87%) [Q3]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $15 12% upside
• Avg. target: $26 97% upside
• High target: $35 161% upside

6 analyst ratings

• positive: 4 67%
• neutral: 2 33%
• negative: 0 0%

Stephens & Co. Sudan Loganathan 50% 1-year accuracy 3 / 6 met price target	12% upside $15	Equal-Weight Reiterated	22 Jan 2025
HC Wainwright & Co. Swayampakula Ramakanth 0 / 0 met price target	146% upside $33	Buy Reiterated	13 Jan 2025
Needham Ami Fadia 0 / 0 met price target	139% upside $32	Buy Reiterated	13 Jan 2025
JMP Securities Reni Benjamin 31% 1-year accuracy 10 / 32 met price target	94% upside $26	Market Outperform Maintained	18 Dec 2024
B. Riley Securities Kalpit Patel 0% 1-year accuracy 0 / 3 met price target	27% upside $17	Neutral Maintained	13 Dec 2024